Mounir El-Hanafi, Abd El-Wahab El-Brashy, Noha Ibrahim, Hamada Khater, Shimaa Mohammed
{"title":"The Relationship between Serum Pentraxin-3 Level and Disease Activity and Severity in Rheumatoid Arthritis Patients","authors":"Mounir El-Hanafi, Abd El-Wahab El-Brashy, Noha Ibrahim, Hamada Khater, Shimaa Mohammed","doi":"10.21608/bjas.2023.216940.1188","DOIUrl":null,"url":null,"abstract":"Background: Pentraxin 3 (PTX3) is an inflammatory marker, a member of long pentraxin superfamily that has an important role in inflammation and immunity. Objectives: The aim of this study was to measure serum pentraxin 3 levels in RA patients and evaluate their relation with different disease parameters. Methods: We measured serum PTX3 levels in 40 women with RA and 40 female control subjects. PTX3concentrations were measures by ELISA. Results: Median serum level of pentrexin 3 was significantly higher in RA patients compared to healthy controls (36.4 ng /ml vs 12.4 ng /ml respectively) (p<0.001). There was a significant difference in serum PTX3 levels according to the disease activity grades. PTX3 concentration was also significantly correlated with ESR(r = 0.506, p=0.001), CRP(r = 0.780, p<0.001) and Larsen Score (r = 0.784, p<0.001). There was no significant difference in serum PTX3 levels and RF& anti-CCP positive and negative patients (P >0.05). No significant correlation (p>0.05) was found between serum Pentraxin-3 and age (r = 0.095), BMI(r = 0.059), disease duration (r = 0.048) and RF titer(r = 0.240). Conclusions: PTX3 can be considered as a sensitive non-invasive biomarker reflecting the disease activity and radiological damage in RA patients.","PeriodicalId":8745,"journal":{"name":"Benha Journal of Applied Sciences","volume":"31 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Benha Journal of Applied Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/bjas.2023.216940.1188","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Pentraxin 3 (PTX3) is an inflammatory marker, a member of long pentraxin superfamily that has an important role in inflammation and immunity. Objectives: The aim of this study was to measure serum pentraxin 3 levels in RA patients and evaluate their relation with different disease parameters. Methods: We measured serum PTX3 levels in 40 women with RA and 40 female control subjects. PTX3concentrations were measures by ELISA. Results: Median serum level of pentrexin 3 was significantly higher in RA patients compared to healthy controls (36.4 ng /ml vs 12.4 ng /ml respectively) (p<0.001). There was a significant difference in serum PTX3 levels according to the disease activity grades. PTX3 concentration was also significantly correlated with ESR(r = 0.506, p=0.001), CRP(r = 0.780, p<0.001) and Larsen Score (r = 0.784, p<0.001). There was no significant difference in serum PTX3 levels and RF& anti-CCP positive and negative patients (P >0.05). No significant correlation (p>0.05) was found between serum Pentraxin-3 and age (r = 0.095), BMI(r = 0.059), disease duration (r = 0.048) and RF titer(r = 0.240). Conclusions: PTX3 can be considered as a sensitive non-invasive biomarker reflecting the disease activity and radiological damage in RA patients.